ERBB2 and cancer: Trastuzumab, an anti-HER2 monoclonal antibody, was the first approved therapeutic agent among multiple classes of anti-HER2 agents and remains the mainstay in the treatment of HER2-positive cancers, along with HER2-directed antibody–drug conjugates (ADCs) and bispecific antibodies [5, 6].